BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

BIM

114.2

+0.79%↑

SRT3

229.2

+0.26%↑

GXI

54

+3.75%↑

ICAD

21.06

-1.5%↓

Search

Sanofi SA

Open

SectorHealthcare

93.14 0.53

Overview

Share price change

24h

Current

Min

91.91

Max

94.26

Key metrics

By Trading Economics

Income

-2.3B

499M

Sales

-6.5B

7.6B

P/E

Sector Avg

20.663

57.333

EPS

1.31

Dividend yield

4.32

Profit margin

6.539

Employees

82,878

EBITDA

-3.7B

563M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+23.14% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.32%

2.63%

Market Stats

By TradingEconomics

Market Cap

-20B

111B

Previous open

92.61

Previous close

93.14

Technical Score

By Trading Central

Confidence

Bearish Evidence

Sanofi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 08:52 UTC

Earnings

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 kwi 2025, 05:44 UTC

Earnings

Sanofi Sales, Profit Beat Expectations

9 kwi 2025, 06:00 UTC

Acquisitions, Mergers, Takeovers

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 mar 2025, 06:43 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 kwi 2025, 12:54 UTC

Market Talk
Earnings

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 kwi 2025, 10:06 UTC

Market Talk
Earnings

Sanofi Starts the Year Strong -- Market Talk

10 kwi 2025, 12:06 UTC

Market Talk
Acquisitions, Mergers, Takeovers

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 kwi 2025, 09:10 UTC

Hot Stocks

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 kwi 2025, 10:49 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 kwi 2025, 08:19 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 kwi 2025, 06:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 kwi 2025, 06:46 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 kwi 2025, 09:07 UTC

Hot Stocks

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 kwi 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 kwi 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2 kwi 2025, 09:27 UTC

Hot Stocks

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mar 2025, 06:19 UTC

Market Talk
Earnings

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mar 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mar 2025, 09:00 UTC

Top News

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mar 2025, 06:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mar 2025, 06:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mar 2025, 06:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Pay $600M Upfront

20 mar 2025, 06:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mar 2025, 06:00 UTC

Acquisitions, Mergers, Takeovers

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mar 2025, 09:33 UTC

Hot Stocks

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mar 2025, 23:00 UTC

Top News

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mar 2025, 09:50 UTC

Earnings

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mar 2025, 09:49 UTC

Earnings

Santander Increased 2024 Cash Payments by 19%

24 lut 2025, 08:56 UTC

Market Talk
Earnings

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 lut 2025, 08:30 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

23.14% upside

12 Months Forecast

Average 114.813 EUR  23.14%

High 127 EUR

Low 83.702 EUR

Based on 14 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

91.62 / N/ASupport & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.